Chargement en cours...

Isradipine Versus Placebo in Early Parkinson Disease A Randomized Trial

BACKGROUND: Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD). OBJECTIVE: To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD. DESIGN: Multicenter, randomiz...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Intern Med
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465126/
https://ncbi.nlm.nih.gov/pubmed/32227247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/M19-2534
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!